{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:07:34Z","timestamp":1791403654666,"version":"4.3.3"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMW","doi-asserted-by":"publisher","award":["114024145 (MKMD)"],"award-info":[{"award-number":["114024145 (MKMD)"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"crossref","award":["201306300062"],"award-info":[{"award-number":["201306300062"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Rationale and objectives<\/jats:title>\n                <jats:p>Fear conditioning is an important aspect in the pathophysiology of anxiety disorders. The fear-potentiated startle test is based on classical fear conditioning and over the years, a broad range of drugs have been tested in this test. Synthesis of the available data may further our understanding of the neurotransmitter systems that are involved in the expression of conditioned fear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Following a comprehensive search in Medline and Embase, we included 68 research articles that reported on 103 drugs, covering 56 different drug classes. The systematic review was limited to studies using acute, systemic drug administration in naive animals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Qualitative data synthesis showed that most clinically active anxiolytics, but not serotonin-reuptake inhibitors, reduced cued fear. Anxiogenic drugs increased fear potentiation in 35% of the experiments, reduced fear potentiation in 29% of the experiments, and were without effect in 29% of the experiments. Meta-analyses could be performed for five drug classes and showed that benzodiazepines, buspirone, 5-HT<jats:sub>1A<\/jats:sub> agonists, 5-HT<jats:sub>1A<\/jats:sub> antagonists, and mGluR2,3 agonists reduced cued conditioned fear. The non-cued baseline startle response, which may reflect contextual anxiety, was only significantly reduced by benzodiazepines and 5-HT<jats:sub>1A<\/jats:sub> antagonists. No associations were found between drug effects and methodological characteristics, except for strain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The fear-potentiated startle test appears to have moderate to high predictive validity and may serve as a valuable tool for the development of novel anxiolytics. Given the limited available data, the generally low study quality and high heterogeneity additional studies are warranted to corroborate the findings of this review.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00213-022-06307-1","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T06:03:13Z","timestamp":1674021793000},"page":"2361-2401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacological modulation of conditioned fear in the fear-potentiated startle test: a systematic review and meta-analysis of animal studies"],"prefix":"10.1007","volume":"240","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-7796","authenticated-orcid":false,"given":"Lucianne","family":"Groenink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Monika","family":"Verdouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freija","family":"ter Heegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley E.","family":"Wever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth Y.","family":"Bijlsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"6307_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/164_2018_104","volume":"247","author":"JP Anand","year":"2018","unstructured":"Anand JP, Montgomery D (2018) Multifunctional opioid ligands. Handb Exp Pharmacol 247:21\u201351. https:\/\/doi.org\/10.1007\/164_2018_104","journal-title":"Handb Exp Pharmacol"},{"key":"6307_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/0014-2999(93)90397-Z","volume":"250","author":"EW Anthony","year":"1993","unstructured":"Anthony EW, Nevins ME (1993) Anxiolytic-like effects of N-methyl-D-aspartate-associated glycine receptor ligands in the rat potentiated startle test. Eur J Pharmacol 250:317\u2013324. https:\/\/doi.org\/10.1016\/0014-2999(93)90397-Z","journal-title":"Eur J Pharmacol"},{"key":"6307_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1124\/jpet.105.089920","volume":"316","author":"JR Atack","year":"2006","unstructured":"Atack JR, Wafford KA, Tye SJ, Cook SM, Sohal B, Pike A, Sur C, Melillo D, Bristow L, Bromidge F, Ragan I, Kerby J, Street L, Carling R, Castro JL, Whiting P, Dawson GR, McKernan RM (2006) TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3- (2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for \u03b12- and 3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. J Pharmacol Exp Ther 316:410\u2013422. https:\/\/doi.org\/10.1124\/jpet.105.089920","journal-title":"J Pharmacol Exp Ther"},{"key":"6307_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/0269881109354928","volume":"25","author":"JR Atack","year":"2011","unstructured":"Atack JR, Hallett DJ, Tye S, Wafford KA, Ryan C, Sanabria-Boh\u00f3rquez SM, Eng WS, Gibson RE, Burns HD, Dawson GR, Carling RW, Street LJ, Pike A, de Lepeleire I, van Laere K, Bormans G, de Hoon JN, van Hecken A, McKernan RM, Murphy MG, Hargreaves RJ (2011) Preclinical and clinical pharmacology of TPA023B, a GABAA receptor \u03b12\/\u03b13 subtype-selective partial agonist. J Psychopharmacol 25:329\u2013344. https:\/\/doi.org\/10.1177\/0269881109354928","journal-title":"J Psychopharmacol"},{"key":"6307_CR5","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1038\/npp.2011.138","volume":"36","author":"LW Ayers","year":"2011","unstructured":"Ayers LW, Missig G, Schulkin J, Rosen JB (2011) Oxytocin reduces background anxiety in a fear-potentiated startle paradigm: peripheral vs central administration. Neuropsychopharmacology 36:2488\u20132497. https:\/\/doi.org\/10.1038\/npp.2011.138","journal-title":"Neuropsychopharmacology"},{"key":"6307_CR6","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1007\/s00213-016-4267-0","volume":"233","author":"L Ayers","year":"2016","unstructured":"Ayers L, Agostini A, Schulkin J, Rosen JB (2016) Effects of oxytocin on background anxiety in rats with high or low baseline startle. Psychopharmacology 233:2165\u20132172. https:\/\/doi.org\/10.1007\/s00213-016-4267-0","journal-title":"Psychopharmacology"},{"issue":"3","key":"6307_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00213-002-1011-8","volume":"161","author":"JMP Baas","year":"2002","unstructured":"Baas JMP, Grillon C, B\u00f6cker KBE, Brack AA, Morgan CA, Kenemans JL, Verbaten MN (2002) Benzodiazepines have no effect on fear-potentiated startle in humans. Psychopharmacology (Berl) 161(3):233\u2013247. https:\/\/doi.org\/10.1007\/s00213-002-1011-8","journal-title":"Psychopharmacology (Berl)"},{"key":"6307_CR8","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.biopsych.2004.02.024","volume":"55","author":"JM Baas","year":"2004","unstructured":"Baas JM, Nugent M, Lissek S, Pine DS, Grillon C (2004) Fear conditioning in virtual reality contexts: a new tool for the study of anxiety. Biol Psychiatry 55:1056\u20131060. https:\/\/doi.org\/10.1016\/j.biopsych.2004.02.024","journal-title":"Biol Psychiatry"},{"key":"6307_CR9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41380-021-01299-4","volume":"27","author":"DR Bach","year":"2022","unstructured":"Bach DR (2022) Cross-species anxiety tests in psychiatry: pitfalls and promises. Mol Psychiatry 27:154\u2013163. https:\/\/doi.org\/10.1038\/s41380-021-01299-4","journal-title":"Mol Psychiatry"},{"key":"6307_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0269881114525674","volume":"28","author":"DS Baldwin","year":"2014","unstructured":"Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, Christmas DM, Davies S, Fineberg N, Lidbetter N, Malizia A, McCrone P, Nabarro D, O\u2019Neill C, Scott J, van der Wee N, Wittchen HU (2014) Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 28:403\u2013439. https:\/\/doi.org\/10.1177\/0269881114525674","journal-title":"J Psychopharmacol"},{"key":"6307_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.31887\/DCNS.2015.17.3\/bbandelow","volume":"17","author":"B Bandelow","year":"2015","unstructured":"Bandelow B, Michaelis S (2015) Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci 17:327\u2013335","journal-title":"Dialogues Clin Neurosci"},{"key":"6307_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/15622975.2016.1190867","volume":"18","author":"B Bandelow","year":"2017","unstructured":"Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, Bourin M, Chamberlain SR, Cinosi E, Davies S, Domschke K, Fineberg N, Gr\u00fcnblatt E, Jarema M, Kim YK, Maron E, Masdrakis V, Mikova O, Nutt D, Pallanti S, Pini S, Str\u00f6hle A, Thibaut F, Vaghi MM, Won E, Wedekind D, Wichniak A, Woolley J, Zwanzger P, Riederer P (2017) Biological markers for anxiety disorders, OCD and PTSD: a consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry 18:162\u2013214. https:\/\/doi.org\/10.1080\/15622975.2016.1190867","journal-title":"World J Biol Psychiatry"},{"key":"6307_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/00004850-200511000-00001","volume":"20","author":"V Bergink","year":"2005","unstructured":"Bergink V, Westenberg HGM (2005) Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740. Int Clin Psychopharmacol 20:291\u2013293. https:\/\/doi.org\/10.1097\/00004850-200511000-00001","journal-title":"Int Clin Psychopharmacol"},{"key":"6307_CR14","doi-asserted-by":"publisher","unstructured":"Bespalov A, Bernard R, Gilis A, Gerlach B, Guill\u00e9n J, Castagn\u00e9 V, Lefevre IA, Ducrey F, Monk L, Bongiovanni S, Altevogt B, Arroyo-Araujo M, Bikovski L, de Bruin N, Casta\u00f1os-V\u00e9lez E, Dityatev A, Emmerich CH, Fares R, Ferland-Beckham C, Froger-Coll\u00e9aux C, Gailus-Durner V, H\u00f6lter SM, Hofmann MCJ, Kabitzke P, Kas MJH, Kurreck C, Moser P, Pietraszek M, Popik P, Potschka H, de Oca EPM, Restivo L, Riedel G, Ritskes-Hoitinga M, Samardzic J, Schunn M, St\u00f6ger C, Voikar V, Vollert J, Wever KE, Wuyts K, Macleod MR, Dirnagl U, Steckler T (2021) Introduction to the eqipd quality system. Elife 10.https:\/\/doi.org\/10.7554\/eLife.63294","DOI":"10.7554\/eLife.63294"},{"key":"6307_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.pbb.2010.04.002","volume":"96","author":"EY Bijlsma","year":"2010","unstructured":"Bijlsma EY, de Jongh R, Olivier B, Groenink L (2010) Fear-potentiated startle, but not light-enhanced startle, is enhanced by anxiogenic drugs. Pharmacol Biochem Behav 96:24\u201331. https:\/\/doi.org\/10.1016\/j.pbb.2010.04.002","journal-title":"Pharmacol Biochem Behav"},{"key":"6307_CR16","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.euroneuro.2015.07.004","volume":"25","author":"EY Bijlsma","year":"2015","unstructured":"Bijlsma EY, Hendriksen H, Baas JMP, Millan MJ, Groenink L (2015) Lifelong disturbance of serotonin transporter functioning results in fear learning deficits: reversal by blockade of CRF1 receptors. Eur Neuropsychopharmacol 25:1733\u20131743. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.07.004","journal-title":"Eur Neuropsychopharmacol"},{"key":"6307_CR17","doi-asserted-by":"publisher","unstructured":"Bijlsma EY, van Leeuwen MLF, Westphal KGC, Olivier B, Groenink L (2011) Local repeated corticotropin-releasing factor infusion exacerbates anxiety- and fear-related behavior: differential involvement of the basolateral amygdala and medial prefrontal cortex. Neuroscience 173.https:\/\/doi.org\/10.1016\/j.neuroscience.2010.11.026","DOI":"10.1016\/j.neuroscience.2010.11.026"},{"key":"6307_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0014-2999(92)90186-8","volume":"218","author":"DJ Bill","year":"1992","unstructured":"Bill DJ, Fletcher A, Glenn BD, Knight M (1992) Behavioural studies on WAY100289, a novel 5-HT3 receptor antagonist, in two animal models of anxiety. Eur J Pharmacol 218:327\u2013334. https:\/\/doi.org\/10.1016\/0014-2999(92)90186-8","journal-title":"Eur J Pharmacol"},{"key":"6307_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1037\/0033-295X.108.1.4","volume":"108","author":"ME Bouton","year":"2001","unstructured":"Bouton ME, Mineka S, Barlow DH (2001) A modern learning theory perspective on the etiology of panic disorder. Psychol Rev 108:4\u201332. https:\/\/doi.org\/10.1037\/0033-295X.108.1.4","journal-title":"Psychol Rev"},{"key":"6307_CR20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.addbeh.2011.12.013","volume":"37","author":"AR Braun","year":"2012","unstructured":"Braun AR, Heinz AJ, Veilleux JC, Conrad M, Weber S, Wardle M, Greenstein J, Evatt D, Drobes D, Kassel JD (2012) The separate and combined effects of alcohol and nicotine on anticipatory anxiety: a multidimensional analysis. Addict Behav 37:485\u2013491. https:\/\/doi.org\/10.1016\/j.addbeh.2011.12.013","journal-title":"Addict Behav"},{"key":"6307_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0091-3057(02)00828-6","volume":"73","author":"J Brodkin","year":"2002","unstructured":"Brodkin J, Busse C, Sukoff SJ, Varney MA (2002) Anxiolytic-like activity of the mGluR5 antagonist MPEP: a comparison with diazepam and buspirone. Pharmacol Biochem Behav 73:359\u2013366. https:\/\/doi.org\/10.1016\/S0091-3057(02)00828-6","journal-title":"Pharmacol Biochem Behav"},{"key":"6307_CR22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1037\/h0060166","volume":"41","author":"JS Brown","year":"1951","unstructured":"Brown JS, Kalish HI, Farber IE (1951) Conditioned fear as revealed by magnitude of startle response to an auditory stimulus. J Exp Psychol 41:317\u2013328. https:\/\/doi.org\/10.1037\/h0060166","journal-title":"J Exp Psychol"},{"key":"6307_CR23","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/sj.npp.1300540","volume":"29","author":"CS Busse","year":"2004","unstructured":"Busse CS, Brodkin J, Tattersall D, Anderson JJ, Warren N, Tehrani L, Bristow LJ, Varney MA, Cosford NDP (2004) The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 29:1971\u20131979. https:\/\/doi.org\/10.1038\/sj.npp.1300540","journal-title":"Neuropsychopharmacology"},{"issue":"3 Pt 2","key":"6307_CR24","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1523\/JNEUROSCI.15-03-02312.1995","volume":"15","author":"S Campeau","year":"1995","unstructured":"Campeau S, Davis M (1995) Involvement of subcortical and cortical afferents to the lateral nucleus of the amygdala in fear conditioning measured with fear-potentiated startle in rats trained concurrently with auditory and visual conditioned stimuli. J Neurosci Off J Soc Neurosci 15(3 Pt 2):2312\u20132327. https:\/\/doi.org\/10.1523\/JNEUROSCI.15-03-02312.1995","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"6307_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1021\/ml100215b","volume":"2","author":"D Carcache","year":"2011","unstructured":"Carcache D, Vranesic I, Blanz J, Desrayaud S, Fendt M, Glatthar R (2011) Benzimidazoles as potent and orally active mGlu5 receptor antagonists with an improved PK profile. ACS Med Chem Lett 2:58\u201362. https:\/\/doi.org\/10.1021\/ml100215b","journal-title":"ACS Med Chem Lett"},{"key":"6307_CR26","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/BF00432707","volume":"87","author":"JV Cassella","year":"1985","unstructured":"Cassella JV, Davis M (1985) Fear-enhanced acoustic startle is not attenuated by acute or chronic imipramine treatment in rats. Psychopharmacology (Berl) 87:278\u2013282. https:\/\/doi.org\/10.1007\/BF00432707","journal-title":"Psychopharmacology (Berl)"},{"key":"6307_CR27","doi-asserted-by":"publisher","unstructured":"Castellano D, Shepard RD, Lu W (2020) Looking for novelty in an \u201cold\u201d receptor: recent advances toward our understanding of GABAARs and their implications in receptor pharmacology. Front Neurosci 14. https:\/\/doi.org\/10.3389\/FNINS.2020.616298","DOI":"10.3389\/FNINS.2020.616298"},{"key":"6307_CR28","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1001\/archpsyc.1984.01790190025003","volume":"41","author":"DS Charney","year":"1984","unstructured":"Charney DS, Heninger GR, Breier A (1984) Noradrenergic function in panic anxiety: effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 41:751\u2013763. https:\/\/doi.org\/10.1001\/archpsyc.1984.01790190025003","journal-title":"Arch Gen Psychiatry"},{"key":"6307_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/BF00215473","volume":"92","author":"DS Charney","year":"1987","unstructured":"Charney DS, Woods SW, Goodman WK, Heninger GR (1987) Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology 92:14\u201324. https:\/\/doi.org\/10.1007\/BF00215473","journal-title":"Psychopharmacology"},{"key":"6307_CR30","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1021\/jm960861b","volume":"40","author":"YL Chen","year":"1997","unstructured":"Chen YL, Mansbach RS, Winter SM, Brooks E, Collins J, Corman ML, Dunaiskis AR, Faraci WS, Gallaschun RJ, Schmidt A, Schulz DW (1997) Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor 1 receptor antagonist. J Med Chem 40:1749\u20131754","journal-title":"J Med Chem"},{"key":"6307_CR31","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/sj.npp.1300655","volume":"30","author":"JP Chhatwal","year":"2005","unstructured":"Chhatwal JP, Davis M, Maguschak KA, Ressler KJ (2005) Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 30:516\u2013524. https:\/\/doi.org\/10.1038\/sj.npp.1300655","journal-title":"Neuropsychopharmacology"},{"key":"6307_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/BF00403634","volume":"7","author":"CC Chi","year":"1965","unstructured":"Chi CC (1965) The effect of amobarbital sodium on conditioned fear as measured by the potentiated startle response in rats. Psychopharmacologia 7:115\u2013122. https:\/\/doi.org\/10.1007\/BF00403634","journal-title":"Psychopharmacologia"},{"key":"6307_CR33","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1021\/jm0110486","volume":"45","author":"I Collado","year":"2002","unstructured":"Collado I, Pedregal C, Maz\u00f3n A, Espinosa JF, Blanco-Urgoiti J, Schoepp DD, Wright RA, Johnson BG, Kingston AE (2002) (2S,1\u2032S,2\u2032S,3\u2032R)-2-(2\u2032-carboxy-3\u2032-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties. J Med Chem 45:3619\u20133629. https:\/\/doi.org\/10.1021\/jm0110486","journal-title":"J Med Chem"},{"key":"6307_CR34","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1021\/jm030967o","volume":"47","author":"I Collado","year":"2004","unstructured":"Collado I, Pedregal C, Bueno AB, Marcos A, Gonz\u00e1lez R, Blanco-Urgoiti J, P\u00e9rez-Castells J, Schoepp DD, Wright RA, Johnson BG, Kingston AE, Moher ED, Hoard DW, Griffey KI, Tizzano JP (2004) (2S,1\u2032S,2\u2032R,3\u2032R)-2-(2\u2032-Carboxy-3\u2032-hydroxymethylcyclopropyl) glycine is a highly potent group 2 and 3 metabotropic glutamate receptor agonist with oral activity. J Med Chem 47:456\u2013466. https:\/\/doi.org\/10.1021\/jm030967o","journal-title":"J Med Chem"},{"key":"6307_CR35","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1021\/jm025570j","volume":"46","author":"NDP Cosford","year":"2003","unstructured":"Cosford NDP, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J, Bristow L, Brodkin J, Jiang X, McDonald I, Rao S, Washburn M, Varney MA (2003) 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 46:204\u2013206. https:\/\/doi.org\/10.1021\/jm025570j","journal-title":"J Med Chem"},{"key":"6307_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00426027","volume":"62","author":"M Davis","year":"1979","unstructured":"Davis M (1979) Diazepam and flurazepam: effects on conditioned fear as measured with the potentiated startle paradigm. Psychopharmacology 62:1\u20137. https:\/\/doi.org\/10.1007\/BF00426027","journal-title":"Psychopharmacology"},{"key":"6307_CR37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1037\/0097-7403.4.2.95","volume":"4","author":"M Davis","year":"1978","unstructured":"Davis M, Astrachan DI (1978) Conditioned fear and startle magnitude: effects of different footshock or backshock intensities used in training. J Exp Psychol Anim Behav Process 4:95\u2013103. https:\/\/doi.org\/10.1037\/0097-7403.4.2.95","journal-title":"J Exp Psychol Anim Behav Process"},{"key":"6307_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/BF00735873","volume":"94","author":"M Davis","year":"1988","unstructured":"Davis M, Cassella JV, Kehne JH (1988) Serotonin does not mediate anxiolytic effects of buspirone in the fear-potentiated startle paradigm: comparison with 8-OH-DPAT and ipsapirone. Psychopharmacology 94:14\u201320. https:\/\/doi.org\/10.1007\/BF00735873","journal-title":"Psychopharmacology"},{"key":"6307_CR39","doi-asserted-by":"publisher","unstructured":"de Jongh R, Groenink L, van der Gugten J, Olivier B (2003) Light-enhanced and fear-potentiated startle: temporal characteristics and effects of \u03b1-helical corticotropin-releasing hormone. Biol Psychiatry 54. https:\/\/doi.org\/10.1016\/S0006-3223(03)00468-2","DOI":"10.1016\/S0006-3223(03)00468-2"},{"issue":"2","key":"6307_CR40","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.bbr.2005.02.004","volume":"161","author":"R de Jongh","year":"2005","unstructured":"de Jongh R, Geyer MA, Olivier B, Groenink L (2005) The effects of sex and neonatal maternal separation on fear-potentiated and light-enhanced startle. Behav Brain Res 161(2):190\u2013196. https:\/\/doi.org\/10.1016\/j.bbr.2005.02.004","journal-title":"Behav Brain Res"},{"key":"6307_CR41","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.pbb.2006.04.012","volume":"84","author":"AR de Oliveira","year":"2006","unstructured":"de Oliveira AR, Reimer AE, Brand\u00e3o ML (2006) Dopamine D2 receptor mechanisms in the expression of conditioned fear. Pharmacol Biochem Behav 84:102\u2013111. https:\/\/doi.org\/10.1016\/j.pbb.2006.04.012","journal-title":"Pharmacol Biochem Behav"},{"key":"6307_CR42","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.euroneuro.2012.05.007","volume":"23","author":"AR de Oliveira","year":"2013","unstructured":"de Oliveira AR, Reimer AE, Reis FMCV, Brand\u00e3o ML (2013) Conditioned fear response is modulated by a combined action of the hypothalamic-pituitary-adrenal axis and dopamine activity in the basolateral amygdala. Eur Neuropsychopharmacol 23:379\u2013389. https:\/\/doi.org\/10.1016\/j.euroneuro.2012.05.007","journal-title":"Eur Neuropsychopharmacol"},{"key":"6307_CR43","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s00221-021-06116-6","volume":"239","author":"VM de Vita","year":"2021","unstructured":"de Vita VM, Zapparoli HR, Adriano, Reimer E, Brand\u00e3o ML, de Oliveira AR (2021) Dopamine D2 receptors in the expression and extinction of contextual and cued conditioned fear in rats. Exp Brain Res 239:1963\u20131974. https:\/\/doi.org\/10.1007\/s00221-021-06116-6","journal-title":"Exp Brain Res"},{"issue":"1","key":"6307_CR44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/0023677213494374","volume":"48","author":"RBM de Vries","year":"2014","unstructured":"de Vries RBM, Hooijmans CR, Tillema A, Leenaars M, Ritskes-Hoitinga M (2014) Updated version of the Embase search filter for animal studies. Lab Anim 48(1):88. https:\/\/doi.org\/10.1177\/0023677213494374","journal-title":"Lab Anim"},{"key":"6307_CR45","doi-asserted-by":"publisher","first-page":"108687","DOI":"10.1016\/j.neuropharm.2021.108687","volume":"196","author":"S Dogra","year":"2021","unstructured":"Dogra S, Conn PJ (2021) Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders. Neuropharmacology 196:108687. https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108687","journal-title":"Neuropharmacology"},{"key":"6307_CR46","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/da.22353","volume":"32","author":"P Duits","year":"2015","unstructured":"Duits P, Cath DC, Lissek S, Hox JJ, Hamm AO, Engelhard IM, van den Hout MA, Baas JMP (2015) Updated meta-analysis of classical fear conditioning in the anxiety disorders. Depress Anxiety 32:239\u2013253. https:\/\/doi.org\/10.1002\/da.22353","journal-title":"Depress Anxiety"},{"key":"6307_CR47","doi-asserted-by":"publisher","unstructured":"Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD (2007) Efficacy and tolerability of an mGlu2\/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 2008 33:7 33, 1603\u20131610. https:\/\/doi.org\/10.1038\/SJ.NPP.130","DOI":"10.1038\/SJ.NPP.130"},{"key":"6307_CR48","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00441-013-1599-5","volume":"354","author":"M Fendt","year":"2013","unstructured":"Fendt M, Koch M (2013) Translational value of startle modulations. Cell Tissue Res 354:287\u2013295. https:\/\/doi.org\/10.1007\/s00441-013-1599-5","journal-title":"Cell Tissue Res"},{"key":"6307_CR49","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/J.NEUROPHARM.2017.07.005","volume":"125","author":"I Gacs\u00e1lyi","year":"2017","unstructured":"Gacs\u00e1lyi I, M\u00f3ricz K, Gigler G, Wellmann J, Nagy K, Ling I, Bark\u00f3czy J, Haller J, Lambert JJ, Sz\u00e9n\u00e1si G, Spedding M, Antoni FA (2017) Behavioural pharmacology of the \u03b15-GABA A receptor antagonist S44819: enhancement and remediation of cognitive performance in preclinical models. Neuropharmacology 125:30\u201338. https:\/\/doi.org\/10.1016\/J.NEUROPHARM.2017.07.005","journal-title":"Neuropharmacology"},{"key":"6307_CR50","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1176\/appi.focus.19203","volume":"19","author":"A Garakani","year":"2020","unstructured":"Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, Iosifescu DV (2020) Pharmacotherapy of anxiety disorders: current and emerging treatment options. Focus 19:222\u2013242. https:\/\/doi.org\/10.1176\/appi.focus.19203","journal-title":"Focus"},{"issue":"7","key":"6307_CR51","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/0006-3223(94)90040-x","volume":"35","author":"C Grillon","year":"1994","unstructured":"Grillon C, Ameli R, Goddard A, Woods SW, Davis M (1994) Baseline and fear-potentiated startle in panic disorder patients. Biol Psychiatry 35(7):431\u2013439. https:\/\/doi.org\/10.1016\/0006-3223(94)90040-x","journal-title":"Biol Psychiatry"},{"key":"6307_CR52","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.brat.2013.09.009","volume":"51","author":"AT Gloster","year":"2013","unstructured":"Gloster AT, Hauke C, H\u00f6fler M, Einsle F, Fydrich T, Hamm A, Sthr\u00f6hle A, Wittchen H-U (2013) Long-term stability of cognitive behavioral therapy effects for panic disorder with agoraphobia: a two-year follow-up study. Behav Res Ther 51:830\u2013839. https:\/\/doi.org\/10.1016\/j.brat.2013.09.009","journal-title":"Behav Res Ther"},{"key":"6307_CR53","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00213-008-1112-0","volume":"198","author":"EM Glover","year":"2008","unstructured":"Glover EM, Davis M (2008) Anxiolytic-like effects of morphine and buprenorphine in the rat model of fear-potentiated startle: tolerance, cross-tolerance, and blockade by naloxone. Psychopharmacology 198:167\u2013180. https:\/\/doi.org\/10.1007\/s00213-008-1112-0","journal-title":"Psychopharmacology"},{"key":"6307_CR54","doi-asserted-by":"crossref","unstructured":"Goldstein LE, Rasmusson AM, Bunney BS, Roth RH (1996) Role of the amygdala in the coordination of behavioral, neuroendocrine, and prefrontal cortical monoamine responses to psychological stress in the rat.","DOI":"10.1523\/JNEUROSCI.16-15-04787.1996"},{"key":"6307_CR55","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nrd4075","volume":"12","author":"G Griebel","year":"2013","unstructured":"Griebel G, Holmes A (2013) 50 Years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discovery 12:667\u2013687. https:\/\/doi.org\/10.1038\/nrd4075","journal-title":"Nat Rev Drug Discovery"},{"issue":"9","key":"6307_CR56","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/S1388-2457(03)00202-5","volume":"114","author":"C Grillon","year":"2003","unstructured":"Grillon C, Baas J (2003) A review of the modulation of the startle reflex by affective states and its application in psychiatry. Clin Neurophysiol 114(9):1557\u20131579. https:\/\/doi.org\/10.1016\/S1388-2457(03)00202-5","journal-title":"Clin Neurophysiol"},{"key":"6307_CR57","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/J.NEUBIOREV.2020.09.024","volume":"119","author":"C Grillon","year":"2020","unstructured":"Grillon C, Ernst M (2020) A way forward for anxiolytic drug development: testing candidate anxiolytics with anxiety-potentiated startle in healthy humans. Neurosci Biobehav Rev 119:348\u2013354. https:\/\/doi.org\/10.1016\/J.NEUBIOREV.2020.09.024","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"6307_CR58","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1037\/\/0021-843x.108.1.134","volume":"108","author":"C Grillon","year":"1999","unstructured":"Grillon C, Morgan CAI (1999) Fear-potentiated startle conditioning to explicit and contextual cues in Gulf War veterans with posttraumatic stress disorder. J Abnorm Psychol 108(1):134\u2013142. https:\/\/doi.org\/10.1037\/\/0021-843x.108.1.134","journal-title":"J Abnorm Psychol"},{"key":"6307_CR59","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s00213-003-1444-8","volume":"168","author":"C Grillon","year":"2003","unstructured":"Grillon C, Cordova J, Levine LR, Morgan CA (2003) Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology 168:446\u2013454. https:\/\/doi.org\/10.1007\/s00213-003-1444-8","journal-title":"Psychopharmacology"},{"issue":"7","key":"6307_CR60","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.biopsych.2005.11.027","volume":"60","author":"C Grillon","year":"2006","unstructured":"Grillon C, Baas JM, Pine DS, Lissek S, Lawley M, Ellis V, Levine J (2006) The benzodiazepine alprazolam dissociates contextual fear from cued fear in humans as assessed by fear-potentiated startle. Biol Psychiatry 60(7):760\u2013766. https:\/\/doi.org\/10.1016\/j.biopsych.2005.11.027","journal-title":"Biol Psychiatry"},{"key":"6307_CR61","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/sj.npp.1301204","volume":"32","author":"C Grillon","year":"2007","unstructured":"Grillon C, Levenson J, Pine DS (2007) A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: a fear-potentiated startle study. Neuropsychopharmacology 32:225\u2013231. https:\/\/doi.org\/10.1038\/sj.npp.1301204","journal-title":"Neuropsychopharmacology"},{"key":"6307_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/0471141755.ph0548s41","author":"L Groenink","year":"2008","unstructured":"Groenink L, Bijlsma EY, Olivier B (2008) Fear-potentiated startle and light-enhanced startle models in drug discovery. Curr Protoc Pharmacol. https:\/\/doi.org\/10.1002\/0471141755.ph0548s41","journal-title":"Curr Protoc Pharmacol"},{"key":"6307_CR63","doi-asserted-by":"publisher","unstructured":"Groenink L, Verdouw PM, Bakker B, Wever KE (2015) Pharmacological and methodological aspects of the separation-induced vocalization test in guinea pig pups; a systematic review and meta-analysis. Eur J Pharmacol 753. https:\/\/doi.org\/10.1016\/j.ejphar.2014.10.062","DOI":"10.1016\/j.ejphar.2014.10.062"},{"key":"6307_CR64","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/00008877-200009000-00006","volume":"11","author":"MR Guscott","year":"2000","unstructured":"Guscott MR, Cook GP, Bristow LJ (2000) Contextual fear conditioning and baseline startle responses in the rat fear-potentiated startle test: a comparison of benzodiazepine\/\u03b3-aminobutyric acid-A receptor agonists. Behav Pharmacol 11:495\u2013504. https:\/\/doi.org\/10.1097\/00008877-200009000-00006","journal-title":"Behav Pharmacol"},{"key":"6307_CR65","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1037\/0735-7044.117.4.704","volume":"117","author":"ALO Hebb","year":"2003","unstructured":"Hebb ALO, Zacharko RM, Bowie JP, Drolet G (2003) Differential startle reactivity following central CCK-8S and systemic Boc CCK-4 administration in mice: antecedent stressor history and testing condition. Behav Neurosci 117:704\u2013715. https:\/\/doi.org\/10.1037\/0735-7044.117.4.704","journal-title":"Behav Neurosci"},{"key":"6307_CR66","unstructured":"Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ, Lilly E (1998) Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. 284:651\u2013660."},{"key":"6307_CR67","doi-asserted-by":"publisher","first-page":"247054702097978","DOI":"10.1177\/2470547020979780","volume":"5","author":"RC Hendrickson","year":"2021","unstructured":"Hendrickson RC, Millard SP, Pagulayan KF, Peskind ER, Raskind MA (2021) The relative effects of prazosin on individual PTSD symptoms: evidence for pathophysiologically-related clustering. Chronic Stress (thousand Oaks) 5:2470547020979780. https:\/\/doi.org\/10.1177\/2470547020979780","journal-title":"Chronic Stress (thousand Oaks)"},{"key":"6307_CR68","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejphar.2015.03.020","volume":"759","author":"H Hendriksen","year":"2015","unstructured":"Hendriksen H, Groenink L (2015) Back to the future of psychopharmacology: a perspective on animal models in drug discovery. Eur J Pharmacol 759:30\u201341. https:\/\/doi.org\/10.1016\/j.ejphar.2015.03.020","journal-title":"Eur J Pharmacol"},{"key":"6307_CR69","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/BF00445558","volume":"99","author":"TH Hijzen","year":"1989","unstructured":"Hijzen TH, Slangen JL (1989) Effects of midazolam, DMCM and lindane on potentiated startle in the rat. Psychopharmacology 99:362\u2013365","journal-title":"Psychopharmacology"},{"key":"6307_CR70","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/BF02245833","volume":"118","author":"TH Hijzen","year":"1995","unstructured":"Hijzen TH, Houtzager SWJ, Joordens RJE, Olivier B, Slangen JL (1995) Predictive validity of the potentiated startle response as a behavioral model for anxiolytic drugs. Psychopharmacology 118:150\u2013154. https:\/\/doi.org\/10.1007\/BF02245833","journal-title":"Psychopharmacology"},{"key":"6307_CR71","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/ARCHPSYC.1981.01780360094011","volume":"38","author":"R Hoehn-Saric","year":"1981","unstructured":"Hoehn-Saric R, Merchant AF, Keyser ML, Smith VK (1981) Effects of clonidine on anxiety disorders. Arch Gen Psychiatry 38:1278\u20131282. https:\/\/doi.org\/10.1001\/ARCHPSYC.1981.01780360094011","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"6307_CR72","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1258\/LA.2010.009117","volume":"44","author":"CR Hooijmans","year":"2010","unstructured":"Hooijmans CR, Tillema A, Leenaars M, Ritskes-Hoitinga M (2010) Enhancing search efficiency by means of a search filter for finding all studies on animal experimentation in PubMed. Lab Anim 44(3):170\u2013175. https:\/\/doi.org\/10.1258\/LA.2010.009117","journal-title":"Lab Anim"},{"key":"6307_CR73","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1073\/pnas.090514397","volume":"97","author":"F Jenck","year":"2000","unstructured":"Jenck F, Wichmann J, Dautzenberg FM, Moreau JL, Ouagazzal AM, Martin JR, Lundstrom K, Cesura AM, Poli SM, Roever S, Koclzewski S, Adam G, Kilpatrick G (2000) A synthetic agonist at the orphanin FQ\/nociceptin receptor ORL51: anxiolytic profile in the rat. Proc Natl Acad Sci U S A 97:4938\u20134943. https:\/\/doi.org\/10.1073\/pnas.090514397","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6307_CR74","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1021\/jm034015u","volume":"46","author":"MP Johnson","year":"2003","unstructured":"Johnson MP, Baez M, Jagdmann GE, Britton TC, Large TH, Callagaro DO, Tizzano JP, Monn JA, Schoepp DD (2003) Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J Med Chem 46:3189\u20133192. https:\/\/doi.org\/10.1021\/jm034015u","journal-title":"J Med Chem"},{"key":"6307_CR75","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00213-004-2099-9","volume":"179","author":"MP Johnson","year":"2005","unstructured":"Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, McKinzie DL, Nisenbaum ES, Tizzano JP, Schoepp DD (2005) Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology 179:271\u2013283. https:\/\/doi.org\/10.1007\/s00213-004-2099-9","journal-title":"Psychopharmacology"},{"key":"6307_CR76","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/BF02246344","volume":"126","author":"RJE Joordens","year":"1996","unstructured":"Joordens RJE, Hijzen TH, Peeters BWMM, Olivier B (1996) Fear-potentiated startle response is remarkably similar in two laboratories. Psychopharmacology 126:104\u2013109. https:\/\/doi.org\/10.1007\/BF02246344","journal-title":"Psychopharmacology"},{"key":"6307_CR77","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1097\/00001756-199703030-00042","volume":"8","author":"RJE Joordens","year":"1997","unstructured":"Joordens RJE, Hijzen TH, Peeters BWMM, Olivier B (1997) Control conditions in the fear-potentiated startle response paradigm. NeuroReport 8:1031\u20131034. https:\/\/doi.org\/10.1097\/00001756-199703030-00042","journal-title":"NeuroReport"},{"key":"6307_CR78","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s002130050729","volume":"139","author":"RJE Joordens","year":"1998","unstructured":"Joordens RJE, Hijzen TH, Olivier B (1998) The effects of 5-HT(1A) receptor agonists, 5-HT(1A) receptor antagonists and their interaction on the fear-potentiated startle response. Psychopharmacology 139:383\u2013390. https:\/\/doi.org\/10.1007\/s002130050729","journal-title":"Psychopharmacology"},{"key":"6307_CR79","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/0196-9781(95)02013-M","volume":"16","author":"S Josselyn","year":"1995","unstructured":"Josselyn S, Frankland P, Petrisano S, Bush D, Yeomans J, Vaccarino F (1995) The CCKB antagonist, L-365,260, attenuates fear-potentiated startle. Peptides 16:1313\u20131315","journal-title":"Peptides"},{"key":"6307_CR80","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4103\/0976-500X.72351","volume":"1","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) The ARRIVE guidelines Animal Research: Reporting In Vivo Experiments. J Pharmacol Pharmacother 1:94\u201399. https:\/\/doi.org\/10.4103\/0976-500X.72351","journal-title":"J Pharmacol Pharmacother"},{"key":"6307_CR81","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1177\/0269881109103115","volume":"24","author":"F Klumpers","year":"2010","unstructured":"Klumpers F, van Gerven JM, Prinssen EPM, Niklson I, Roesch F, Riedel WJ, Kenemans JL, Baas JMP (2010) Method development studies for repeatedly measuring anxiolytic drug effects in healthy humans. J Psychopharmacology 24:657\u2013666. https:\/\/doi.org\/10.1177\/0269881109103115","journal-title":"J Psychopharmacology"},{"key":"6307_CR82","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1037\/0097-7403.11.3.421","volume":"11","author":"RN Leaton","year":"1985","unstructured":"Leaton RN, Borszcz GS (1985) Potentiated startle. Its relation to freezing and shock intensity in rats. J Exp Psychol Anim Behav Process 11:421\u2013428. https:\/\/doi.org\/10.1037\/0097-7403.11.3.421","journal-title":"J Exp Psychol Anim Behav Process"},{"key":"6307_CR83","doi-asserted-by":"publisher","first-page":"181","DOI":"10.31887\/DCNS.2017.19.2\/wcarlezon","volume":"19","author":"KR Lezak","year":"2017","unstructured":"Lezak KR, Missig G, Carlezon WA Jr (2017) Behavioral methods to study anxiety in rodents. Dialogues Clin Neurosci 19:181\u2013192","journal-title":"Dialogues Clin Neurosci"},{"key":"6307_CR84","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/J.NEUROPHARM.2015.05.001","volume":"97","author":"X Li","year":"2015","unstructured":"Li X, Kaczanowska K, Finn MG, Markou A, Risbrough VB (2015) The GABA(B) receptor positive modulator BHF177 attenuated anxiety, but not conditioned fear, in rats. Neuropharmacology 97:357\u2013364. https:\/\/doi.org\/10.1016\/J.NEUROPHARM.2015.05.001","journal-title":"Neuropharmacology"},{"key":"6307_CR85","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/da.21922","volume":"29","author":"S Lissek","year":"2012","unstructured":"Lissek S (2012) Toward an account of clinical anxiety predicated on basic, neurally mapped mechanisms of Pavlovian fear-learning: the case for conditioned overgeneralization. Depress Anxiety 29:257\u2013263. https:\/\/doi.org\/10.1002\/da.21922","journal-title":"Depress Anxiety"},{"key":"6307_CR86","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/jnc.13516","volume":"139","author":"G Llovera","year":"2016","unstructured":"Llovera G, Liesz A (2016) The next step in translational research: lessons learned from the first preclinical randomized controlled trial. J Neurochem 139:271\u2013279. https:\/\/doi.org\/10.1111\/jnc.13516","journal-title":"J Neurochem"},{"key":"6307_CR87","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.neubiorev.2017.02.026","volume":"77","author":"TB Lonsdorf","year":"2017","unstructured":"Lonsdorf TB, Menz MM, Andreatta M, Fullana MA, Golkar A, Haaker J, Heitland I, Hermann A, Kuhn M, Kruse O, Drexler SM, Ann Meulders A, Nees F, Pittig A, Richter J, R\u00f6mer S, Shiban Y, Schmitz A, Straube B, Vervliet B, Wendt J, Baas JMP, Merz CJ (2017) Don\u2019t fear \u201cfear conditioning\u201d: methodological considerations for the design and analysis of studies on human fear acquisition, extinction, and return of fear. Neurosci Biobehav Rev 77:247\u2013285. https:\/\/doi.org\/10.1016\/j.neubiorev.2017.02.026","journal-title":"Neurosci Biobehav Rev"},{"key":"6307_CR88","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejphar.2011.04.034","volume":"661","author":"SX Lu","year":"2011","unstructured":"Lu SX, Higgins GA, Hodgson RA, Hyde LA, del Vecchio RA, Guthrie DH, Kazdoba T, McCool MF, Morgan CA, Bercovici A, Ho GD, Tulshian D, Parker EM, Hunter JC, Varty GB (2011) The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1] octane-3-carboxamide (SCH 655842): comparison of efficacy and side effects across rodent species. Eur J Pharmacol 661:63\u201371. https:\/\/doi.org\/10.1016\/j.ejphar.2011.04.034","journal-title":"Eur J Pharmacol"},{"key":"6307_CR89","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3758\/s13415-011-0021-6","volume":"11","author":"L Luyten","year":"2011","unstructured":"Luyten L, Vansteenwegen D, van Kuyck K, Gabri\u00ebls L, Nuttin B (2011) Contextual conditioning in rats as an animal model for generalized anxiety disorder. Cogn Affect Behav Neurosci 11:228\u2013244. https:\/\/doi.org\/10.3758\/s13415-011-0021-6","journal-title":"Cogn Affect Behav Neurosci"},{"key":"6307_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pbio.1002273","volume":"13","author":"MR Macleod","year":"2015","unstructured":"Macleod MR, Lawson McLean A, Kyriakopoulou A, Serghiou S, de Wilde A, Sherratt N, Hirst T, Hemblade R, Bahor Z, Nunes-Fonseca C, Potluru A, Thomson A, Baginskitae J, Egan K, Vesterinen H, Currie GL, Churilov L, Howells DW, Sena ES (2015) Risk of bias in reports of in vivo research: a focus for improvement. PLoS Biol 13:1\u201312. https:\/\/doi.org\/10.1371\/journal.pbio.1002273","journal-title":"PLoS Biol"},{"key":"6307_CR91","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0014-2999(88)90283-X","volume":"156","author":"RS Mansbach","year":"1988","unstructured":"Mansbach RS, Geyer MA (1988) Blockade of potentiated startle responding in rats by 5-hydroxytryptamine1A receptor ligands. Eur J Pharmacol 156:375\u2013383. https:\/\/doi.org\/10.1016\/0014-2999(88)90283-X","journal-title":"Eur J Pharmacol"},{"key":"6307_CR92","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0091-3057(01)00713-4","volume":"71","author":"JR Martin","year":"2002","unstructured":"Martin JR, Ballard TM, Higgins GA (2002) Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol Biochem Behav 71:615\u2013625. https:\/\/doi.org\/10.1016\/S0091-3057(01)00713-4","journal-title":"Pharmacol Biochem Behav"},{"key":"6307_CR93","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/S40429-021-00366-8","volume":"8","author":"IM Meier","year":"2021","unstructured":"Meier IM, Eikemo M, Leknes S (2021) The role of mu-opioids for reward and threat processing in humans: bridging the gap from preclinical to clinical opioid drug studies. Curr Addict Rep 8:306\u2013318. https:\/\/doi.org\/10.1007\/S40429-021-00366-8","journal-title":"Curr Addict Rep"},{"key":"6307_CR94","doi-asserted-by":"crossref","unstructured":"Merali Z, Bedard T, Andrews N, Davis B, McKnight AT, Gonzalez MI, Pritchard M, Kent P, Anisman H (2006) Bombesin receptors as a novel anti-anxiety therapeutic target: BB1 receptor actions on anxiety through alterations of serotonin activity. J Neurosci 26, 10387\u201310396. 26\/41\/10387 [pii]\\r10.1523\/JNEUROSCI.1219\u201306.2006","DOI":"10.1523\/JNEUROSCI.1219-06.2006"},{"key":"6307_CR95","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.actpsy.2007.11.007","volume":"127","author":"S Mineka","year":"2008","unstructured":"Mineka S, Oehlberg K (2008) The relevance of recent developments in classical conditioning to understanding the etiology and maintenance of anxiety disorders. Acta Psychol (amst) 127:567\u2013580. https:\/\/doi.org\/10.1016\/j.actpsy.2007.11.007","journal-title":"Acta Psychol (amst)"},{"key":"6307_CR96","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1038\/npp.2010.155","volume":"35","author":"G Missig","year":"2010","unstructured":"Missig G, Ayers LW, Schulkin J, Rosen JB (2010) Oxytocin reduces background anxiety in a fear-potentiated startle paradigm. Neuropsychopharmacology 35:2607\u20132616. https:\/\/doi.org\/10.1038\/npp.2010.155","journal-title":"Neuropsychopharmacology"},{"key":"6307_CR97","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.neuroscience.2013.11.063","volume":"261","author":"S Muthuraju","year":"2014","unstructured":"Muthuraju S, Nobre MJ, Saito VMN, Brandao ML (2014) Distinct effects of haloperidol in the mediation of conditioned fear in the mesolimbic system and processing of unconditioned aversive information in the inferior colliculus. Neuroscience 261:195\u2013206. https:\/\/doi.org\/10.1016\/j.neuroscience.2013.11.063","journal-title":"Neuroscience"},{"key":"6307_CR98","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s00213-003-1633-5","volume":"172","author":"K Myers","year":"2004","unstructured":"Myers K, Goulet M, Rusche J, Boismenu R, Davis M (2004) Inhibition of fear potentiated startle in rats following peripheral administration of secretin. Psychopharmacology 172:94\u201399. https:\/\/doi.org\/10.1007\/s00213-003-1633-5","journal-title":"Psychopharmacology"},{"key":"6307_CR99","doi-asserted-by":"publisher","unstructured":"Nagase H, Saitoh A (2020) Research and development of \u03ba opioid receptor agonists and \u03b4 opioid receptor agonists. Pharmacol Ther 205. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2019.107427","DOI":"10.1016\/J.PHARMTHERA.2019.107427"},{"key":"6307_CR100","doi-asserted-by":"publisher","unstructured":"Nasir M, Trujillo D, Levine J, Dwyer JB, Rupp ZW, Bloch MH (2020) Glutamate systems in DSM-5 anxiety disorders: their role and a review of glutamate and GABA psychopharmacology. Front Psychiatry 11. https:\/\/doi.org\/10.3389\/FPSYT.2020.548505","DOI":"10.3389\/FPSYT.2020.548505"},{"key":"6307_CR101","first-page":"248","volume":"268","author":"ME Nevins","year":"1994","unstructured":"Nevins ME, Anthony EW (1994) Antagonists at the serotonin-3 receptor can reduce the fear-potentiated startle response in the rat: evidence for different types of anxiolytic activity? J Pharmacol Exp Ther 268:248\u2013254","journal-title":"J Pharmacol Exp Ther"},{"key":"6307_CR102","doi-asserted-by":"publisher","unstructured":"Newman-Tancredi A, Depoort\u00e8re RY, Kleven MS, Ko\u0142aczkowski M, Zimmer L (2022) Translating biased agonists from molecules to medications: serotonin 5-HT1A receptor functional selectivity for CNS disorders. Pharmacol Ther 229. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107937","DOI":"10.1016\/j.pharmthera.2021.107937"},{"key":"6307_CR103","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/1471-244X-14-S1-S1","volume":"13","author":"C Otte","year":"2011","unstructured":"Otte C (2011) Cognitive behavioral therapy in anxiety disorders: current state of the evidence. Dialogues Clin Neurosci 13:413\u2013421. https:\/\/doi.org\/10.1186\/1471-244X-14-S1-S1","journal-title":"Dialogues Clin Neurosci"},{"key":"6307_CR104","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.neuron.2014.10.007","volume":"84","author":"DE Pankevich","year":"2014","unstructured":"Pankevich DE, Altevogt BM, Dunlop J, Gage FH, Hyman SE (2014) Improving and accelerating drug development for nervous system disorders. Neuron 84:546\u2013553. https:\/\/doi.org\/10.1016\/j.neuron.2014.10.007","journal-title":"Neuron"},{"key":"6307_CR105","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/BF00428536","volume":"83","author":"S Pellow","year":"1984","unstructured":"Pellow S, File SE (1984) Multiple sites of action for anxiogenic drugs: behavioural, electrophysiological and biochemical correlations. Psychopharmacology 83:304\u2013315. https:\/\/doi.org\/10.1007\/BF00428536","journal-title":"Psychopharmacology"},{"key":"6307_CR106","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0304-3940(85)90303-9","volume":"55","author":"S Pellow","year":"1985","unstructured":"Pellow S, Chopin P, File SE (1985) Are the anxiogenic effects of yohimbine mediated by its action at benzodiazepine receptors? Neurosci Lett 55:5\u20139. https:\/\/doi.org\/10.1016\/0304-3940(85)90303-9","journal-title":"Neurosci Lett"},{"key":"6307_CR107","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1111\/BPH.15193","volume":"177","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, W\u00fcrbel H (2020) The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. Br J Pharmacol 177:3617\u20133624. https:\/\/doi.org\/10.1111\/BPH.15193","journal-title":"Br J Pharmacol"},{"key":"6307_CR108","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejphar.2005.03.028","volume":"514","author":"M Pietraszek","year":"2005","unstructured":"Pietraszek M, Sukhanov I, Maciejak P, Szyndler J, Gravius A, Wis\u0142owska A, P\u0142a\u017anik A, Bespalov AY, Danysz W (2005) Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur J Pharmacol 514:25\u201334. https:\/\/doi.org\/10.1016\/j.ejphar.2005.03.028","journal-title":"Eur J Pharmacol"},{"key":"6307_CR109","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1176\/appi.ajp.160.2.371","volume":"160","author":"MA Raskind","year":"2003","unstructured":"Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson CE, Dobie DJ, Hoff D, Rein RJ, Straits-Tr\u00f6ster K, Thomas RG, McFall MM (2003) Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry 160:371\u2013373. https:\/\/doi.org\/10.1176\/appi.ajp.160.2.371","journal-title":"Am J Psychiatry"},{"key":"6307_CR110","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1507598","volume":"378","author":"MA Raskind","year":"2018","unstructured":"Raskind MA, Peskind ER, Chow B, Harris C, Davis-Karim A, Holmes HA, Hart KL, McFall M, Mellman TA, Reist C, Romesser J, Rosenheck R, Shih MC, Stein MB, Swift R, Gleason T, Lu Y, Huang GD (2018) Trial of prazosin for post-traumatic stress disorder in military veterans. N Engl J Med 378:507\u2013517. https:\/\/doi.org\/10.1056\/NEJMoa1507598","journal-title":"N Engl J Med"},{"key":"6307_CR111","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852920001121","author":"C Reist","year":"2021","unstructured":"Reist C, Streja E, Tang CC, Shapiro B, Mintz J, Hollifield M (2021) Prazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis. CNS Spectr. https:\/\/doi.org\/10.1017\/S1092852920001121","journal-title":"CNS Spectr"},{"key":"6307_CR112","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s002130100816","volume":"157","author":"J Riba","year":"2001","unstructured":"Riba J, Rodr\u00edguez-Fornells A, Urbano G, Morte A, Antonijoan R, Barbanoj MJ (2001) Differential effects of alprazolam on the baseline and fear-potentiated startle reflex in humans: a dose-response study. Psychopharmacology 157:358\u2013367. https:\/\/doi.org\/10.1007\/s002130100816","journal-title":"Psychopharmacology"},{"key":"6307_CR113","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.biopsych.2004.10.006","volume":"57","author":"VB Risbrough","year":"2005","unstructured":"Risbrough VB, Geyer MA (2005) Anxiogenic treatments do not increase fear-potentiated startle in mice. Biol Psychiat 57:33\u201343. https:\/\/doi.org\/10.1016\/j.biopsych.2004.10.006","journal-title":"Biol Psychiat"},{"key":"6307_CR114","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/sj.npp.1300079","volume":"28","author":"VB Risbrough","year":"2003","unstructured":"Risbrough VB, Brodkin JD, Geyer MA (2003) GABA-A and 5-HTIA receptor agonists block expression of fear-potentiated startle in mice. Neuropsychopharmacology 28:654\u2013663. https:\/\/doi.org\/10.1038\/sj.npp.1300079","journal-title":"Neuropsychopharmacology"},{"key":"6307_CR115","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/npp.2008.205","volume":"34","author":"VB Risbrough","year":"2009","unstructured":"Risbrough VB, Geyer MA, Hauger RL, Coste S, Stenzel-Poore M, Wurst W, Holsboer F (2009) CRF 1 and CRF 2 receptors are required for potentiated startle to contextual but not discrete cues. Neuropsychopharmacology 34:1494\u20131503. https:\/\/doi.org\/10.1038\/npp.2008.205","journal-title":"Neuropsychopharmacology"},{"key":"6307_CR116","doi-asserted-by":"publisher","first-page":"4645","DOI":"10.1021\/jm049828c","volume":"47","author":"J Roppe","year":"2004","unstructured":"Roppe J, Smith ND, Huang D, Tehrani L, Wang B, Anderson J, Brodkin J, Chung J, Jiang X, King C, Munoz B, Varney MA, Prasit P, Cosford NDP (2004) Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem 47:4645\u20134648. https:\/\/doi.org\/10.1021\/jm049828c","journal-title":"J Med Chem"},{"key":"6307_CR117","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1016\/j.bmcl.2004.05.037","volume":"14","author":"JR Roppe","year":"2004","unstructured":"Roppe JR, Wang B, Huang D, Tehrani L, Kamenecka T, Schweiger EJ, Anderson JJ, Brodkin J, Jiang X, Cramer M, Chung J, Reyes-Manalo G, Munoz B, Cosford NDP (2004) 5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3\u2032-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity. Bioorg Med Chem Lett 14:3993\u20133996. https:\/\/doi.org\/10.1016\/j.bmcl.2004.05.037","journal-title":"Bioorg Med Chem Lett"},{"key":"6307_CR118","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00213-007-0758-3","volume":"193","author":"LM Rorick-Kehn","year":"2007","unstructured":"Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, McKinzie DL, Schoepp DD (2007) In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2\/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology 193:121\u2013136. https:\/\/doi.org\/10.1007\/s00213-007-0758-3","journal-title":"Psychopharmacology"},{"key":"6307_CR119","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/NRD3502","volume":"10","author":"U Rudolph","year":"2011","unstructured":"Rudolph U, Knoflach F (2011) Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov 10:685\u2013697. https:\/\/doi.org\/10.1038\/NRD3502","journal-title":"Nat Rev Drug Discov"},{"key":"6307_CR120","doi-asserted-by":"publisher","first-page":"107402","DOI":"10.1016\/J.PHARMTHERA.2019.107402","volume":"204","author":"SB Sartori","year":"2019","unstructured":"Sartori SB, Singewald N (2019) Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol Ther 204:107402. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2019.107402","journal-title":"Pharmacol Ther"},{"key":"6307_CR121","doi-asserted-by":"crossref","unstructured":"Schulz B, Fendt M, Gasparini F, Lingenh\u00f6hl K, Kuhn R, Koch M (2001) The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats. Neuropharmacology 41, 1\u20137. S0028390801000363 [pii]","DOI":"10.1016\/S0028-3908(01)00036-3"},{"key":"6307_CR122","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.pbb.2008.05.025","volume":"90","author":"PD Shilling","year":"2008","unstructured":"Shilling PD, Feifel D (2008) The neurotensin-1 receptor agonist PD149163 blocks fear-potentiated startle. Pharmacol Biochem Behav 90:748\u2013752. https:\/\/doi.org\/10.1016\/j.pbb.2008.05.025","journal-title":"Pharmacol Biochem Behav"},{"key":"6307_CR123","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/01.FBP.0000081783.35927.8F","volume":"14","author":"W Spooren","year":"2003","unstructured":"Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, Schreiber R (2003) Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 14:257\u2013277. https:\/\/doi.org\/10.1097\/01.FBP.0000081783.35927.8F","journal-title":"Behav Pharmacol"},{"key":"6307_CR124","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/J.BBR.2011.02.021","volume":"221","author":"MA Steiner","year":"2011","unstructured":"Steiner MA, Lecourt H, Rakotoariniaina A, Jenck F (2011) Favoured genetic background for testing anxiolytics in the fear-potentiated and light-enhanced startle paradigms in the rat. Behav Brain Res 221:34\u201342. https:\/\/doi.org\/10.1016\/J.BBR.2011.02.021","journal-title":"Behav Brain Res"},{"key":"6307_CR125","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00213-012-2736-7","volume":"223","author":"MA Steiner","year":"2012","unstructured":"Steiner MA, Lecourt H, Jenck F (2012) The brain orexin system and almorexant in fear-conditioned startle reactions in the rat. Psychopharmacology 223:465\u2013475. https:\/\/doi.org\/10.1007\/s00213-012-2736-7","journal-title":"Psychopharmacology"},{"key":"6307_CR126","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/cmdc.201300003","volume":"8","author":"MA Steiner","year":"2013","unstructured":"Steiner MA, Gatfield J, Brisbare-Roch C, Dietrich H, Treiber A, Jenck F, Boss C (2013) Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. ChemMedChem 8:898\u2013903. https:\/\/doi.org\/10.1002\/cmdc.201300003","journal-title":"ChemMedChem"},{"key":"6307_CR127","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/NRD3480","volume":"10","author":"DC Swinney","year":"2011","unstructured":"Swinney DC, Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discov 10:507\u2013519. https:\/\/doi.org\/10.1038\/NRD3480","journal-title":"Nat Rev Drug Discov"},{"key":"6307_CR128","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0091-3057(02)00850-X","volume":"73","author":"JP Tizzano","year":"2002","unstructured":"Tizzano JP, Griffey KI, Schoepp DD (2002) The anxiolytic action of mGlu2\/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam. Pharmacol Biochem Behav 73:367\u2013374. https:\/\/doi.org\/10.1016\/S0091-3057(02)00850-X","journal-title":"Pharmacol Biochem Behav"},{"key":"6307_CR129","doi-asserted-by":"publisher","unstructured":"Toufexis DJ, Lipatova O, Johnson AC, Abizaid A (2016) Food-restriction lowers the acoustic startle response in both male and female rats, and, in combination with acute ghrelin injection, abolishes the expression of fear-potentiated startle in male rats. J Neuroendocrinol 28.https:\/\/doi.org\/10.1111\/JNE.12436","DOI":"10.1111\/JNE.12436"},{"key":"6307_CR130","doi-asserted-by":"publisher","unstructured":"Ubaldi M, Cannella N, Borruto AM, Petrella M, Micioni Di Bonaventura MV, Soverchia L, Stopponi S, Weiss F, Cifani C, Ciccocioppo R (2021) Role of nociceptin\/orphanin FQ-NOP receptor system in the regulation of stress-related disorders.Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/IJMS222312956","DOI":"10.3390\/IJMS222312956"},{"key":"6307_CR131","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/00008877-199603000-00004","volume":"7","author":"AL Vale","year":"1996","unstructured":"Vale AL, Green S (1996) Effects of chlordiazepoxide, nicotine and d-amphetamine in the rat potentiated startle model of anxiety. Behav Pharmacol 7:138\u2013143. https:\/\/doi.org\/10.1097\/00008877-199603000-00004","journal-title":"Behav Pharmacol"},{"key":"6307_CR132","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/BF02805991","volume":"127","author":"IM van Vliet","year":"1996","unstructured":"van Vliet IM, Westenberg HGM, den Boer JA (1996) Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder. Psychopharmacology 127:174\u2013180. https:\/\/doi.org\/10.1007\/BF02805991","journal-title":"Psychopharmacology"},{"key":"6307_CR133","doi-asserted-by":"publisher","unstructured":"Varty GB, Lu SX, Morgan CA, Cohen-Williams ME, Hodgson RA, Smith-torhan A, Zhang H, Fawzi AB, Graziano MP, Ho GD, Matasi J, Tulshian D, Coffin VL, Carey GJ (2008) The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510). 326, 672\u2013682. https:\/\/doi.org\/10.1124\/jpet.108.136937.affinity","DOI":"10.1124\/jpet.108.136937.affinity"},{"key":"6307_CR134","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1523\/jneurosci.22-06-02343.2002","volume":"22","author":"DL Walker","year":"2002","unstructured":"Walker DL, Ressler KJ, Lu KT, Davis M (2002) Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 22:2343\u20132351. https:\/\/doi.org\/10.1523\/jneurosci.22-06-02343.2002","journal-title":"J Neurosci"},{"issue":"2","key":"6307_CR135","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1101\/LM.87105","volume":"12","author":"DL Walker","year":"2005","unstructured":"Walker DL, Paschall GY, Davis M (2005) Glutamate receptor antagonist infusions into the basolateral and medial amygdala reveal differential contributions to olfactory vs. context fear conditioning and expression. Learn Memory (Cold Spring Harbor, N.Y.) 12(2):120\u2013129. https:\/\/doi.org\/10.1101\/LM.87105","journal-title":"Learn Memory (Cold Spring Harbor, N.Y.)"},{"key":"6307_CR136","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/npp.2008.210","volume":"34","author":"D Walker","year":"2009","unstructured":"Walker D, Yang Y, Ratti E, Corsi M, Trist D, Davis M (2009) Differential effects of the CRF-R1 antagonist GSK876008 on fear-potentiated, light- and CRF-enhanced startle suggest preferential involvement in sustained vs phasic threat responses. Neuropsychopharmacology 34:1533\u20131542. https:\/\/doi.org\/10.1038\/npp.2008.210","journal-title":"Neuropsychopharmacology"},{"key":"6307_CR137","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1007\/S00213-018-4942-4","volume":"235","author":"M Willadsen","year":"2018","unstructured":"Willadsen M, Best LM, W\u00f6hr M, Clarke PBS (2018) Effects of anxiogenic drugs on the emission of 22- and 50-kHz ultrasonic vocalizations in adult rats. Psychopharmacology 235:2435\u20132445. https:\/\/doi.org\/10.1007\/S00213-018-4942-4","journal-title":"Psychopharmacology"},{"key":"6307_CR138","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/BF00427414","volume":"10","author":"P Willner","year":"1986","unstructured":"Willner P (1986) Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Prog Neuropsychopharmacol Biol Psychiatry 10:677\u2013690. https:\/\/doi.org\/10.1007\/BF00427414","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"6307_CR139","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.cell.2016.06.026","volume":"166","author":"J Zhang","year":"2016","unstructured":"Zhang J, Tan L, Ren Y, Liang J, Lin R, Feng Q, Zhou J, Hu F, Ren J, Wei C, Yu T, Zhuang Y, Bettler B, Wang F, Luo M (2016) Presynaptic excitation via GABAB receptors in habenula cholinergic neurons regulates fear memory expression. Cell 166:716\u2013728. https:\/\/doi.org\/10.1016\/j.cell.2016.06.026","journal-title":"Cell"},{"key":"6307_CR140","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/J.BBR.2018.05.022","volume":"351","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Bijlsma EY, Verdouw MP, Groenink L (2018) No effect of sex and estrous cycle on the fear potentiated startle response in rats. Behav Brain Res 351:24\u201333. https:\/\/doi.org\/10.1016\/J.BBR.2018.05.022","journal-title":"Behav Brain Res"},{"key":"6307_CR141","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.bbr.2018.06.035","volume":"353","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Bijlsma EY, Verdouw PM, Garssen J, Groenink L (2018) The contribution of contextual fear in the anxiolytic effect of chlordiazepoxide in the fear-potentiated startle test. Behav Brain Res 353:57\u201361. https:\/\/doi.org\/10.1016\/j.bbr.2018.06.035","journal-title":"Behav Brain Res"},{"key":"6307_CR142","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/S00213-018-5124-0","volume":"236","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Bijlsma EY, ter Heegde F, Verdouw MP, Garssen J, Newman-Tancredi A, Groenink L (2019) Activation of somatodendritic 5-HT 1A autoreceptors reduces the acquisition and expression of cued fear in the rat fear-potentiated startle test. Psychopharmacology 236:1171\u20131185. https:\/\/doi.org\/10.1007\/S00213-018-5124-0","journal-title":"Psychopharmacology"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06307-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-022-06307-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06307-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T08:02:23Z","timestamp":1698048143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-022-06307-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":142,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["6307"],"URL":"https:\/\/doi.org\/10.1007\/s00213-022-06307-1","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"4 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}